Expanding expertise across scientific, technical, and operational areas is an important step in supporting the scale-up of innovation and advancing new therapies toward clinical application. As Fetalix continues to grow, the company is strengthening the multidisciplinary team behind the development of its technology.
Supported by the Portugal 2030-funded FET-DISC project, Fetalix has welcomed Diana Rodrigues, who will contribute to the continued development of the company's fetal-inspired regenerative biomaterial.
Diana brings extensive experience in designing and conducting preclinical in vivo studies, with a strong background in pain research and animal models. At Fetalix, she will lead the company's in vivo validation efforts, helping generate the evidence needed to advance the regenerative technology toward clinical translation.
The continued growth of the Fetalix team reflects the company's commitment to building the capabilities needed to translate scientific innovation into clinical impact.
August 6, 2026
